RT Journal Article
SR Electronic
T1 International healthcare workers’ experiences and perceptions of the 2022 multi-country mpox outbreak
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.23.24312504
DO 10.1101/2024.08.23.24312504
A1 Apea, Vanessa
A1 Titanji, Boghuma K.
A1 Dakin, Francesca H.
A1 Hayes, Rosalie
A1 Smuk, Melanie
A1 Kawu, Habiba
A1 Waters, Laura
A1 Levy, Itsik
A1 Kuritzkes, Daniel R.
A1 Gandhi, Monica
A1 Rockstroh, Jürgen
A1 Schechter, Mauro
A1 Holt, Martin
A1 Palich, Romain
A1 Cortes, Claudia P.
A1 Nozza, Silvia
A1 Mussini, Cristina
A1 Calmy, Aleaxandra
A1 Crabtree Ramirez, Brenda E.
A1 Blanco, José L.
A1 Bhagani, Sanjay
A1 Dewsnap, Claire
A1 Orkin, Chloe
A1 ,
YR 2024
UL http://medrxiv.org/content/early/2024/08/23/2024.08.23.24312504.abstract
AB In May 2022, the most widespread outbreak of sustained transmission of mpox outside of countries historically affected countries in Western and Central Africa occurred. We aimed to examine the personal and clinical experiences of international healthcare workers (HCWs) during this public health emergency. We conducted an international cross-sectional survey study between August and October 2022, examining the experiences and perceptions of HCWs clinically involved with the 2022 mpox response. Respondents were recruited via an international network of sexual health and HIV clinicians responding to mpox and promoted through clinical associations and social media. Survey domains included: clinical workload; preparedness; training and support at work; psychological well-being and vaccination. 725 multi-national healthcare workers across 41 countries were included in the analysis. 91% were physicians specialised in Sexual Health or Infectious Diseases; with 34% (n=247) of all respondents involved in mpox policy. A substantial proportion of respondents (n=296, 41%) reported working longer hours during the mpox outbreak, with no concomitant removal of other clinical responsibilities. 30% (n=218) of respondents reported that they had never heard of mpox before the outbreak and over 25% of the respondents reported that they had misdiagnosed someone initially. This culminated in a high prevalence of moral distress at 30%. Less than 9% of HCWs in the region of the Caribbean, Central America and South America had been offered a vaccine as compared to almost 1/3 in the other regions. Where offered, there were high levels of uptake across all regions. Our findings highlight a critical need for addressing the profound gaps in HCW knowledge about re-emerging diseases with pandemic potential. Strengthening the resilience of global health systems and prioritising internationally coordinated approaches to global vaccine deployment is imperative.Competing Interest StatementNilFunding StatementThere was no funding source for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The survey was administered via a survey platform compliant with general data protection regulations (SMART Survey LTD, Tewkesbury, UK) and received ethical approval from the Queen Mary University of London Ethics of Research Committee (QMERC22.297).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe protocol, all survey questions examined in this analysis and relevant data are available online at https://osf.io/jf6kw.